文献速递妇科

宫颈癌患者淋巴结转移分层为大转移、微转移或孤立肿瘤细胞无临床意义:SCCAN项目亚组分析

Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project.
PubMed 文献 · Gynecol Oncol · 2022-11-25

该研究分析SCCAN数据库中967例宫颈癌患者,评估前哨淋巴结转移大小与无病生存的关系。发现转移灶≥0.4 mm与无病生存显著缩短相关,但传统按大小分层(大转移、微转移、孤立肿瘤细胞)无临床意义。

要点

  • 淋巴结转移≥0.4 mm与无病生存显著缩短相关(HR 2.311,P=0.04)。
  • 大转移与微转移患者无病生存无显著差异(P=0.484)。
  • 孤立肿瘤细胞亚组无病生存与N0无显著差异(P=0.127)。

核心结论

  • 宫颈癌患者淋巴结转移灶≥0.4 mm与无病生存显著负相关,未发现转移大小具有优于其余N1患者的预后切点。
  • 传统按转移大小分层(大转移、微转移、孤立肿瘤细胞)无临床意义。

研究设计与样本

  • 对SCCAN(Surveillance in Cervical CANcer)数据库中967例宫颈癌患者(T1a1L1-T2b)进行亚组分析。
  • 患者均接受初次手术治疗,包括前哨淋巴结活检及病理超分期。
  • 将前哨淋巴结转移大小视为连续变量,对0.01-1.0 mm的切点值进行多重检验。
  • 比较N0与按切点范围定义的N1亚组之间的无病生存。

主要发现

  • 172例(18%)患者发现淋巴结转移,其中大转移79例、微转移54例、孤立肿瘤细胞39例。
  • 大转移患者无病生存较短(HR 2.20,P=0.003),微转移患者无病生存较短(HR 2.87,P<0.001)。
  • 大转移与微转移患者无病生存无显著差异(P=0.484)。
  • 孤立肿瘤细胞亚组无病生存与N0无显著差异(P=0.127),与微转移/大转移亚组也无显著差异(P=0.449)。
  • 所有转移灶≥0.4 mm的亚组与N0相比无病生存显著缩短(HR 2.311,P=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 转移灶<0.4 mm的意义因统计效能有限(<80%)无法评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In cervical cancer, presence of lymph-node macrometastases (MAC) is a major prognostic factor and an indication for adjuvant treatment. However, since clinical impact of micrometastases (MIC) and isolated tumor-cells (ITC) remains controversial, we sought to identify a cut-off value for the metastasis size not associated with negative prognosis. METHODS: We analyzed data from 967 cervical cancer patients (T1a1L1-T2b) registered in the SCCAN (Surveillance in Cervical CANcer) database, who underwent primary surgical treatment, including sentinel lymph-node (SLN) biopsy with pathological ultrastaging. The size of SLN metastasis was considered a continuous variable and multiple testing was performed for cut-off values of 0.01-1.0 mm. Disease-free survival (DFS) was compared between N0 and subgroups of N1 patients defined by cut-off ranges. RESULTS: LN metastases were found in 172 (18%) patients, classified as MAC, MIC, and ITC in 79, 54, and 39 patients, respectively. DFS was shorter in patients with MAC (HR 2.20, P = 0.003) and MIC (HR 2.87, P < 0.001), while not differing between MAC/MIC (P = 0.484). DFS in the ITC subgroup was neither different from N0 (P = 0.127) nor from MIC/MAC subgroups (P = 0.449). Cut-off analysis revealed significantly shorter DFS compared to N0 in all subgroups with metastases ≥0.4 mm (HR 2.311, P = 0.04). The significance of metastases <0.4 mm could not be assessed due to limited statistical power (<80%). We did not identify any cut-off for the size of metastasis with significantly better prognosis than the rest of N1 group. CONCLUSIONS: In cervical cancer patients, the presence of LN metastases ≥0.4 mm was associated with a significant negative impact on DFS and no cut-off value for the size of metastasis with better prognosis than N1 was found. Traditional metastasis stratification based on size has no clinical implication.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Dostálek L, Benešová K, Klát J, et al. Stratification of lymph node metastases as macrometastases, micrometastases, or isolated tumor cells has no clinical implication in patients with cervical cancer: Subgroup analysis of the SCCAN project. Gynecol Oncol. 2022. PMID: 36442426. doi:10.1016/j.ygyno.2022.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。